E
Excision Biotherapeutics
Developing CRISPR-based therapies intended to cure viral infectious diseases
About Excision Biotherapeutics
Excision BioTherapeutics is a biotechnology startup that operates in the field of gene therapy. The company's primary focus is on developing a functional cure for HIV, a feat they have already achieved in animals. They use a revolutionary gene-editing technology called CRISPR, which they have licensed from the Doudna Lab at UC Berkeley and the Khalili Lab at Temple University.
CRISPR, which stands for Clustered Regularly Interspaced Short Palindromic Repeats, is a technology that allows scientists to edit genes within organisms. In simple terms, it's like a pair of molecular scissors that can cut out harmful genes and replace them with healthy ones. Excision BioTherapeutics uses this technology to target and remove the HIV genome from the body, thereby curing the disease.
The company's business model is based on the development and commercialization of its gene therapies. Once a therapy is developed, it can be sold to healthcare providers who administer it to patients. The company's primary market is individuals living with HIV, but the technology has the potential to be used to cure other infectious diseases as well.
Excision BioTherapeutics generates revenue by selling its gene therapies. The therapies require only a one-time edit to remove the viral genome permanently, which could make them a cost-effective solution for healthcare providers and patients.
In conclusion, Excision BioTherapeutics is a pioneering biotech startup that is using cutting-edge gene-editing technology to develop a functional cure for HIV. The company's innovative approach has the potential to revolutionize the treatment of infectious diseases and bring much-needed therapies to patients around the world.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Sep 2022 | $6.9M | — | California Institute for Regenerative Medicine | ↗ |
| EARLY VCOther financing | Feb 2021 | $60M | $240M | Norwest Venture Partners · Olive Tree Capital · Artis Ventures · Cota Capital | — |
Growth signals
Latest recorded traffic for Excision Biotherapeutics is 130 monthly website visits, down 98% over the last three months. Excision Biotherapeutics's team declined 40% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Excision Biotherapeutics in the Watertown ecosystem
The Excision Biotherapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed7 investors entered at this stage
Oakhouse Partners
Artis Ventures
Gaingels
Alumni Ventures- BKBenjamin Kong
- BIBioverge
California Institute for Regenerative Medicine
Series A9 investors entered at this stage
Norwest Venture Partners
Olive Tree Capital
Cota Capital
IndusAge Partners- LHLoreda Holdings
Celesta Capital
Anzu Partners
GreatPoint Ventures
Adjuvant Capital
Series B and later1 investor entered at this stage
Ben Franklin Technology Partners of Southeastern Pennsylvania
Other known investors1 additional known investor
Stanford University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Excision Biotherapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Excision Biotherapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.






